EWM
CRSP icon

Endurance Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Endurance Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300
Closed -$34K – 632
2021
Q3 		$34K Hold
300
– – ﹤0.01% 389
2021
Q2 		$48K Hold
300
– – 0.01% 363
2021
Q1 		$37K Buy
+300
New +$45.3K ﹤0.01% 387

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Endurance Wealth Management's CRSP Position: Q4 2021 in Review

Endurance Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 300 shares — an estimated $34K sold.

Endurance Wealth Management first reported a position in CRSP in Q1 2021 and held it in 3 quarters. The position peaked at $48K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Endurance Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Endurance Wealth Management sold 300 CRISPR Therapeutics shares in Q4 2021, an estimated $34K.
  • Endurance Wealth Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 3 quarters.
  • Endurance Wealth Management's CRISPR Therapeutics position peaked at $48K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Endurance Wealth Management's 13F filing for Q4 2021, filed 19 Jan 2022.